Document is current
Any future updates will be listed below
-
Authors
Javaheripour, Nooshin
Colic, Lejla https://orcid.org/0000-0002-8809-4034
Opel, Nils https://orcid.org/0000-0003-4749-3298
Li, Meng https://orcid.org/0000-0002-8320-5241
Maleki Balajoo, Somayeh
Chand, Tara
Van der Meer, Johan
Krylova, Marina
Izyurov, Igor
Meller, Tina
Goltermann, Janik
Winter, Nils R.
Meinert, Susanne https://orcid.org/0000-0003-2177-7161
Grotegerd, Dominik
Jansen, Andreas
Alexander, Nina
Usemann, Paula
Thomas-Odenthal, Florian
Evermann, Ulrika https://orcid.org/0000-0002-3250-7821
Wroblewski, Adrian https://orcid.org/0000-0002-0371-7686
Brosch, Katharina https://orcid.org/0000-0002-0526-8095
Stein, Frederike
Hahn, Tim https://orcid.org/0000-0001-6541-3795
Straube, Benjamin https://orcid.org/0000-0002-9837-0944
Krug, Axel https://orcid.org/0000-0002-0564-2497
Nenadić, Igor
Kircher, Tilo
Croy, Ilona
Dannlowski, Udo
Wagner, Gerd https://orcid.org/0000-0003-2296-0259
Walter, Martin https://orcid.org/0000-0001-7857-4483
- License Information
-
More Information
Article History
Received: 5 June 2023
Revised: 21 June 2023
Accepted: 22 June 2023
First Online: 17 July 2023
Competing interests
: MW is a member of the following advisory boards and gave presentations to the following companies: Bayer AG, Germany; Boehringer Ingelheim, Germany; and Biologische Heilmittel Heel GmbH, Germany. MW has further conducted studies with institutional research support from HEEL and Janssen Pharmaceutical Research for a clinical trial (IIT) on ketamine in patients with MDD, unrelated to this investigation. MW did not receive any financial compensation from the companies mentioned above. All other authors report no biomedical financial interests or other potential conflicts of interest.
